Fluorescent biomarkers that help clinicians find and remove cancer
Summit Biomedical Imaging develops PARP-targeting fluorescent biomarkers to improve cancer detection, surgical precision, and patient outcomes.
Fluorescent biomarkers transform cancer surgery
PARP-targeted fluorescence helps surgeons visualize and remove cancer tissue with greater precision, improving outcomes for patients.
Real-time tumor visualization
Surgeons see fluorescent signals from cancer cells during procedures, enabling confident tissue identification and complete removal.
Reduced incomplete resection
PARP-targeted biomarkers highlight cancer cells that might be missed, lowering the risk of tumor recurrence after surgery.
Faster surgical decision-making
Instant fluorescent feedback eliminates guesswork, allowing surgeons to confidently distinguish cancer from healthy tissue in real time.
Improved patient outcomes
By removing more cancer tissue in a single surgery, patients experience fewer repeat procedures and better long-term survival rates.
PARP enzyme targeting
Summit Biomedical Imaging's biomarkers specifically bind to PARP, an enzyme overexpressed by most cancers, ensuring high specificity and minimal false signals.
Clinical validation in progress
Summit Biomedical Imaging is advancing fluorescent biomarkers through rigorous testing to meet FDA standards and bring this technology to operating rooms.
Advancing Cancer Detection Through Fluorescent Innovation
Summit Biomedical Imaging is pioneering PARP-targeted fluorescent biomarkers that enable clinicians to detect and remove cancers with greater precision and confidence.
1
Biomedical innovation team
Dedicated to developing next-generation fluorescent diagnostics for cancer care.
PARP
Enzyme target
Over-expressed in many cancers, enabling precise fluorescence-guided detection and removal.
100%
Focus on outcomes
Every biomarker developed targets improved patient outcomes and surgical precision.
Ready to advance cancer detection? Connect with Summit Biomedical Imaging today.
Whether you're a clinician, researcher, or institution exploring fluorescent biomarker technology, we're here to discuss how our PARP-targeted solutions can improve patient outcomes.
Built on science. Driven by patient outcomes.
Summit Biomedical Imaging was founded on a simple principle: fluorescent biomarkers can transform how clinicians detect and remove cancer. We're focused on one mission—becoming the world leader in fluorescence-based diagnostics and surgical support. Every innovation we develop is designed to improve patient outcomes and give clinicians the clarity they need in the operating room.